Platform

Drug Intelligent Science (DIS™)

Transforming drug discovery and development through single-cell analytics

We are transforming discovery and development by combining our Data Intelligence with our Single-Cell Science to achieve optimal outcomes for target discovery, drug candidate identification, lead optimization, and patient selection.

Our DIS™ strategy overcomes several significant challenges of drug discovery and development, including:

  • Patient heterogeneity
  • Substantial scaling requirements
  • Difficulty of identifying predictive biomarkers

Core Applications

DIS
Dis Applications

Discover targets associated with disease mechanisms directly from individual patient samples

  • Apply single-cell technology to patient sample analysis for dissecting the difference between disease cells vs normal cells
  • Leverage drug response and resistance signatures to define novel targeting hypothesis

Pioneering single-cell target deconvolution strategy

  • Novel approach to identify the targets of antibodies uniquely produced by patients

Single-Cell Based Target Deconvolution


Deep immune repertoire mining in species agnostic manner

Proven ultra-high throughput antibody selection for challenging targets such as multi-transmembrane proteins

Our innovative single-cell platform provides the ability to rapidly screen for multispecific antibodies and optimize their functional activity in the droplet setting. Our approach has the unique capability to capture precise biological interactions of two different cell types, on the same cell or different cells contained within each droplet, and generate outputs reflecting more accurately the relevant disease biology.

Current approaches for bispecific antibody engineering lack the ability to optimize simultaneous target engagement and functional readouts in the bispecific format and rather focus on each arm separately prior to bispecific formatting.

Our approach masters the process of simultaneous optimization of two or more targeting arms in a well-defined setting reflecting accurate mechanism of action, which substantially reduces the lead optimization time.

The process for stable cell line generation related to biologics manufacturing is a critical and time- and resource-consuming task. Our proprietary single-cell platform could identify and isolate high-level antibody producing cells from a large heterogeneous cell population at a high throughput.

The innovative technology can be used to sort and expand cells that produce functional antibodies with desired properties, resulting in a faster and more streamlined process.

Pioneering novel biomarker development increases probability of success in clinical trials, matching therapies to patients.

  • Dissect heterogeneity of diseases using patient samples by combining genotype and phenotype
  • Sophisticated algorithms exploit rich data structure to precisely position drugs to maximize patient benefit
  • Synergistic collaborations with top academic institutions and world-class clinicians

Novel Single-Cell Approach to Identify Biomarker and Patient Stratification

Our single-cell capabilities provide innovative solutions by allowing broad immune cell profiling, functional screening, and deep sequencing-based phenotypic characterization.

  • Millions of cells can be analyzed per experiment with 5000+ droplets per second
  • Agnostic with respect to species and source of cells
  • Flexible in-droplet assay types; Ability to profile secreted products
  • Barcoded single-cell sequencing maintains native antibody or TCR pairing
  • Rapid turnaround time from screening to sequence

Our technology addresses a series of unmet needs and bottlenecks at the single-cell level. We apply our droplet-based microfluidic technology with other cutting-edge single-cell methods for a variety of applications enabling or supporting drug discovery and drug development.

  • Fit-for-purpose technology
  • Ultra-high throughput phenotypic and functional single-cell screening
  • Unprecedented single-cell profiling capabilities

Fueled by data from our single-cell technology, we unleash the power of artificial intelligence and machine learning for better target and biomarker discovery.

  • Resolve complex biology by deep phenotypic characterization of different immune cell types paired with functional readout
  • Sophisticated algorithms exploit the rich data structure of single-cell data
  • In silico analytical capabilities guide fast-paced engineering and results in activity optimized drug designs
  • Results in therapeutics that are precisely tailored to benefit patients

CelliGOTM Overview

Our technology addresses a series of unmet needs and bottlenecks at the single-cell level through innovative solutions that allow broad immune cell profiling, functional screening, and deep sequence-based phenotypic characterization. We apply our droplet-based microfluidic technology with other cutting-edge single-cell methods for a variety of drug discovery and drug development applications.

Partnership Highlights

Kite and HiFiBio Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia

Read More

Research Collaboration to Develop Technology for the Treatment of Cancer

Read More

Research Collaboration to Develop Technology for the Treatment of Cancer

Read More

Read our article in Drug Discovery Today for more information on our open-innovation strategy

Read More

Partnerships

Establishing strategic partnerships with leading pharmaceutical and biotechnology companies, as well as academic institutions.